Australian medical company, Nanosonics (NAN), has already achieved an impressive 22.7% market penetration of US hospitals

Matthijs Smith

Canaccord Genuity Australia

Australian medical company, Nanosonics (NAN), has already achieved an impressive 22.7% market penetration of US hospitals. Nanosonic (NAN) reports 1296 hospitals (ex 5723) now have at least one Trophon ultrasound sterilising device. This is 31% up on October 2013. As most hospitals have the potential to purchase many units, with larger hospitals purchasing as many as 50 instruments, this initial install base should deliver robust future sales from existing customers. This is in addition to new hospital customers that may be acquired. The company announced a solid result for H1 FY14 with sales revenue up 119% v pcp to $9.7M, and gross profit up 100% to $6.0M. The company has a sound cash position with $21.6M in the bank and a net cash burn of $2.3M for the half. Sales from Europe are expected to grow this year. There is also the possibility of approval in Japan this year.


Matthijs Smith
Senior Life Sciences Analyst
Canaccord Genuity Australia

PhD Human Genetics, MBA, BSc Hons (1st Class). Sell side analyst specialising in life science companies since 2006. Previous background in biotech companies, medical research, consulting with BCG and scientific journalism with Nature

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.